A case of refractory alopecia areata successfully treated by combining delgocitinib ointment with excimer laser

• 資料種別: 記事
• タイトル: A case of refractory alopecia areata successfully treated by combining delgocitinib ointment with excimer laser
• 著者標目: Kakeji, Yukito; Kogame, Toshiaki; Yagi, Yosuke; Kambe, Naotomo; https://orcid.org/0000-0001-9610-4952; Kabashima, Kenji; https://orcid.org/0000-0002-0773-0554
• 出版年月日等: 2025-04
• 出版年（W3CDTF）: 2025-04
• タイトル（掲載誌）: Skin Health and Disease
• 巻号年月日等（掲載誌）: 5 2
• 掲載巻: 5
• 掲載号: 2
• 掲載ページ: 154-157
• 掲載年月日（W3CDTF）: 2025-04
• 出版事項（掲載誌）: Wiley
• 本文の言語コード: en
• 対象利用者: 一般
• オンライン閲覧公開範囲: インターネット公開
• 著作権情報: © The Author(s) 2025. Published by Oxford University Press on behalf of British Association of Dermatologists. This is an Open Access article distribute under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
• 関連情報（URI）: http://hdl.handle.net/2433/294304
• 連携機関・データベース: 国立情報学研究所 : CiNii Research; https://cir.nii.ac.jp/
• 提供元機関・データベース: 学術機関リポジトリデータベース; https://irdb.nii.ac.jp

• 要約等: Alopecia areata (AA) is an autoimmune disease that causes recurrent hair loss. No treatment has been effective in the long term because of the unstable efficacy and possible side effects. AA is primarily driven by Th1-type inflammation, centred around CD8⁺ T cells and interferon-γ (IFN-γ). Recent studies have revealed that the Janus kinase (JAK) family is also involved in the pathogenesis of AA, leading to JAK inhibitors emerging as a treatment for AA. We present a case of a 39-year-old Japanese woman with severe AA who exhibited a Severity of Alopecia Tool (SALT) score 80 accompanied by atopic dermatitis (AD). Despite conventional treatments, the condition worsened from a SALT score of 80 to 100. We subsequently attempted treatment with an excimer laser (EL), but no hair regrowth was observed. However, the introduction of 0.5% delgocitinib ointment in combination with EL led to complete hair regrowth beginning 2 months later, with complete remission achieved after 1 year. This case highlights the potential efficacy of combining delgocitinib ointment with EL in treating severe AA, particularly in patients with AD. The findings suggest that this combination therapy may provide a safer and more effective alternative to oral JAK inhibitors. Nevertheless, further studies are needed to elucidate the underlying mechanisms and fully evaluate the therapeutic synergy.
• 記録形式（IMT）: application/pdf
• 一次資料へのリンクURL: vzaf013.pdf （fulltext）; https://repository.kulib.kyoto-u.ac.jp/bitstreams/5a9a35dc-9f00-4f8d-a584-0a585d9c22f9/download
• オンライン閲覧公開範囲: インターネット公開
• 著作権情報: © The Author(s) 2025. Published by Oxford University Press on behalf of British Association of Dermatologists. This is an Open Access article distribute under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
• 関連情報（DOI）: 10.1093/skinhd/vzaf013; https://doi.org/10.1093/skinhd/vzaf013
• 連携機関・データベース: 国立情報学研究所 : 学術機関リポジトリデータベース（IRDB）（機関リポジトリ）; https://irdb.nii.ac.jp
• 提供元機関・データベース: 京都大学 : 京都大学学術情報リポジトリ